Streetbeat News

Regulatory

NTLA

Intellia Therapeutics has received authorization from the UK MHRA to initiate a Phase 1/2 clinical trial of NTLA-3001 for treating Alpha-1 Antitrypsin Deficiency.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:41 am

AVXL

Anavex Life Sciences reported promising preclinical results for ANAVEX2-73 (Blarcamesine) in a model of Fragile X Syndrome (FXS), showing potential to address behavioral and cognitive deficits. The company plans to initiate a clinical trial in individuals with FXS.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:41 am

NTLA

Intellia Therapeutics has received authorization to initiate a Phase 1/2 clinical trial for NTLA-3001, a treatment for Alpha-1 Antitrypsin Deficiency.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:41 am

PEG

Public Service Enterprise Group (PSEG) reaffirmed its FY24 adjusted EPS guidance of $3.60-$3.70, aligning with the $3.67 estimate. The company successfully managed extreme conditions, including a heat wave and a significant earthquake, with minimal disruption. PSEG's regulatory calendar is on track, and the company is set to implement another gas supply cost reduction in October.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:35 am

AMD

CRWD

FFIV

LSCC

MSFT

RMBS

SANM

TLRY

Nasdaq and S&P futures rise as traders anticipate earnings from Microsoft and AMD, and the Federal Reserve's rate-setting meeting. Positive sentiment is driven by expectations of rate cuts in September. Key companies reporting earnings include Microsoft, AMD, and others. F5, Inc. jumps in premarket trading, while Rambus, Lattice Semiconductor, and others decline.

Portfolio Pulse from Shanthi Rexaline

July 30, 2024 | 11:27 am

GUTS

Fractyl Health shares are trading higher after the company received FDA Device Designation for Revita, aimed at weight maintenance for people with obesity who discontinue GLP-1 based drugs.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:25 am

ARMP

Armata Pharmaceuticals has received an additional $5.25 million in non-dilutive funding from a Department of Defense grant to support the development of its phage candidate, AP-SA02, for treating complicated Staphylococcus aureus bacteremia.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:16 am

QXO

QXO Inc. (NASDAQ:QXO), a company associated with Jared Kushner, experienced an 80% drop in pre-market trading, reducing its valuation from $90 billion to $8.6 billion. The decline was triggered by the registration of two private placements with the SEC, unlocking millions of shares and increasing selling pressure.

Portfolio Pulse from Benzinga Neuro

July 30, 2024 | 11:13 am

BCDA

BioCardia has submitted a 510(K) application for approval of its patented Morph DNA Steerable Introducer Sheath, which is designed to facilitate the introduction of medical instruments into the peripheral and coronary vasculature.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:09 am

GUTS

Fractyl Health has received FDA device designation for its Revita treatment, aimed at weight maintenance for people with obesity who discontinue GLP-1 based drugs.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:05 am